Mikkel Zöllner Ankarfeldt (Mikkel Z Ankarfeldt)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Low Birth Weight

Cross Sectional

Metabolic Syndrome

Body Mass Index

Top Venues

Drugs - real world outcomes

Pharmacoepidemiology and drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Mikkel Zöllner Ankarfeldt, Aleksander Søltoft-Jensen, Claudia A Salinas, Angela Lupattelli, Eero Pukkala, Kristian Bolin, Sarah Smith, Kristin Joy Meyers, Janne Petersen, Espen Jimenez-Solem
Effectiveness of Baricitinib Risk Minimization Activities in Patients With Rheumatoid Arthritis-A Cohort Study in Four Nordic Countries. Pharmacoepidemiology and drug safety 33 (9) (2024)
Mikkel Zöllner Ankarfeldt, Janne Petersen, Jon Trærup Andersen, Maria Fernanda Scantamburlo Fernandes, Hu Li, Stephen Paul Motsko, Thomas Fast, Espen Jimenez-Solem
Duloxetine Exposure During Pregnancy and the Risk of Offspring Being Born Small for Gestational Age or Prematurely: A Nationwide Danish and Swedish Safety Study. Drugs - real world outcomes (2022)
Mikkel Zöllner Ankarfeldt, Janne Petersen, Jon Trærup Andersen, Maria Fernanda Scantamburlo Fernandes, Hu Li, Stephen Paul Motsko, Thomas Fast, Espen Jimenez-Solem
Duloxetine Exposure During Pregnancy and the Risk of Spontaneous and Elective Abortion: A Danish Nationwide Observational Study. Drugs - real world outcomes 8 (3) (2021)
Mikkel Zöllner Ankarfeldt, Janne Petersen, Jon Trærup Andersen, Hu Li, Stephen Paul Motsko, Thomas Fast, Simone Møller Hede, Espen Jimenez-Solem
Exposure to duloxetine during pregnancy and risk of congenital malformations and stillbirth: A nationwide cohort study in Denmark and Sweden. PLoS medicine 18 (11) (2021)